Samarth Kulkarni, CRISPR Therapeutics AG's Chief Executive Officer and a director of the company, recently disposed of 798 shares of the company. The disposals took place at $130.25 per share, on March 01, 2021. Kulkarni still owns 182,191 shares of the company. Kulkarni operates out of Cambridge, MA. Some additional info was provided as follows:
On December 1, 2017, the reporting person was granted 26,667 restricted stock units. On March 1, 2021, 1,666 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever CRISPR Therapeutics AG makes a similar move, sign up!
Other recent filings from the company include the following:
CRISPR Therapeutics AG's Chief Executive Officer just cashed-in 30,000 options - June 17, 2021
CRISPR Therapeutics AG director just disposed of 10,000 shares - June 15, 2021
CRISPR Therapeutics AG director was just granted 10,000 options - June 14, 2021
Amendments to Articles of Incorporation or - June 14, 2021
Statement of changes in beneficial ownership of securities - June 14, 2021